Novartis To Close R&D Facility In Japan By Year’s End
This article was originally published in PharmAsia News
The Swiss company Novartis says it will close its research-and-development facility in Japan by the end of 2008. In doing so, Novartis would be joining several other major multinational pharmaceutical manufacturers in closing R&D facilities in the country. The Novartis Tsukuba Research Institute, was established in 1993 to develop new drugs for the company's Japanese subsidiary, Novartis Pharma KK. The Japan R&D work is to be merged with Novartis operations in the United States as part of a cost-cutting move. (Click here for more - may require a subscription
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.